M
Manel Rakez
Publications - 4
Citations - 41
Manel Rakez is an academic researcher. The author has contributed to research in topics: Oxaliplatin & Colorectal cancer. The author has an hindex of 3, co-authored 4 publications receiving 18 citations.
Papers
More filters
Journal ArticleDOI
Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group.
Thierry André,Dewi Vernerey,S-A. Im,G. Bodoky,Roberto Buzzoni,S. Reingold,Fernando Rivera,Joseph McKendrick,W. Scheithauer,G. Ravit,G. Fountzilas,W.P. Yong,Randi Isaacs,Pia Österlund,Jin-Tung Liang,G.J.M. Creemers,Manel Rakez,E. Van Cutsem,David Cunningham,J. Tabernero,A. de Gramont +20 more
TL;DR: No benefit of the bevacizumab addition to FOLFOX4 adjuvant therapy in patients with stage III CC was observed in terms of DFS with a negative effect in OS, without increase in non-CC related deaths.
Journal ArticleDOI
Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer (CRC): An analysis of 18,399 patients in the ARCAD database.
Anna Dorothea Wagner,Manel Rakez,Benoist Chibaudel,Richard Adams,John Zalcberg,Leonard B. Saltz,Alan P. Venook,Hans-Joachim Schmoll,Jean-Yves Douillard,Christophe Tournigand,Volker Heinemann,Richard M. Goldberg,J. Randolph Hecht,Chiara Cremolini,Eduardo Díaz-Rubio,Axel Grothey,Qian Shi,Aimery de Gramont +17 more
TL;DR: The clearance of 5-FU differs significantly between men (M) and women (W) and adjuvant chemotherapy for CRC has a higher toxicity in W.
Journal ArticleDOI
Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
Benoist Chibaudel,Julie Henriques,Manel Rakez,Baruch Brenner,Tae Won Kim,Mercedes Martinez-Villacampa,Javier Gallego-Plazas,Andrés Cervantes,Katharine Shim,Derek J. Jonker,Veronique Guerin-Meyer,Laurent Mineur,Chiara Banzi,Alice Dewdney,Thitiya Dejthevaporn,Haiko J. Bloemendal,Arnaud Roth,Markus Moehler,Enrique Aranda,Eric Van Cutsem,Josep Tabernero,Hans-Joachim Schmoll,Paulo M. Hoff,Thierry André,Aimery de Gramont +24 more
TL;DR: It is suggested that adding bevacizumab to oxaliplatin-based chemotherapy was not associated with longer DFS or OS in patients with high-risk stage II Colon cancer and that the definition of high- risk stage II colon cancer needs to be revisited.
Journal ArticleDOI
Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients.
Ofer Margalit,Ben Boursi,Manel Rakez,André Thierry,Greg Yothers,Norman Wolmark,Daniel G. Haller,Hans-Joachim Schmoll,Qian Shi,Einat Shacham-Shmueli,Aimery de Gramont +10 more
TL;DR: In this article, the authors used Cox regression model to evaluate the magnitude of survival differences between IDEA risk groups, according to oxaliplatin use, and found that low-risk patients may be offered only 3 months of treatment.